Urogen Pharma Ltd (URGN) Q1 2026 Earnings Call Transcript

Why It Matters

The permanent J code removes a key reimbursement barrier, unlocking scalable revenue for Zasturi and positioning UroGen for long‑term growth in the NMIBC market. Strengthened financing supports commercial expansion and accelerates pipeline milestones that could broaden the company’s oncology portfolio.

Key Takeaways

• Permanent J code drives Zasturi adoption surge.
• Zasturi revenue $15.8M in 2025, early 2026 growth.
• Over 95% of covered lives now have Zasturi access.
• New $250M loan lowers cost of capital, extends repayment.
• UGN‑103 Phase 3 shows 77.8% complete response, NDA 2026

Pulse Analysis

The bladder‑cancer landscape is evolving as non‑muscle invasive disease (NMIBC) demands less invasive, office‑based therapies. Zasturi’s six‑dose regimen, now backed by a permanent Medicare J code, eliminates the previous reimbursement uncertainty that slowed physician uptake. Early commercial metrics—838 active sites, 102 unique prescribers, and a rapid shift from hospital‑centric to community‑centric administration—signal that urologists are embracing the convenience and efficacy demonstrated in the ENVISION trial, where roughly 80% of patients achieved complete response at three months.

Financially, UroGen’s 2025 results reflect a modest but meaningful start, with Zasturi contributing $15.8 million and Jelmyto delivering $94 million in net product revenue. The company’s 2026 guidance anticipates Jelmyto growth to $97‑101 million and operating expenses of $240‑250 million, driven by salesforce expansion and pipeline investments. A newly secured $250 million senior secured term loan at an 8.25% fixed rate replaces higher‑cost debt, extending principal repayment to 2030 and preserving cash—now $120.5 million—for strategic initiatives without diluting shareholders.

Looking ahead, UroGen’s pipeline could amplify its market footprint. UGN‑103, a next‑generation mitomycin formulation, posted a 77.8% complete response in the Phase 3 Utopia trial, positioning it for an NDA submission in 2026 and potential FDA approval in 2027. Parallel efforts on UGN‑104 and the oncolytic virus candidate UGN‑501 broaden the addressable NMIBC spectrum, from low‑grade to high‑risk disease. If commercial traction for Zasturi meets its projected trajectory, the company’s $1 billion peak‑revenue outlook becomes increasingly credible, offering investors a compelling blend of near‑term cash flow and long‑term growth potential.